A positive result and a patentable result are not the same thing. If you're a researcher who thinks you might have something worth protecting, that distinction is the first thing to understand, and the earlier you understand it, the more options you have.
 

What Does "Novel" Actually Mean in Patent Law?

 

It's Not Just About Being First

A patentable result is not the same as a scientific discovery. A scientific discovery is new knowledge, something that hasn't been published or demonstrated before. A patentable result meets a higher, two-part legal standard: it must be novel (not already present in the prior art) and non-obvious (not a predictable next step for someone trained in the field). Meeting one requirement without the other is not enough to secure a patent.

This is where most researchers with a promising result start, and where the first misconception lives.

In patent terms, novelty means an invention cannot already exist, in its entirety, within a single piece of prior art. Prior art is anything publicly available: papers, existing patents, conference abstracts, products on the market. If every element of a claimed invention appears together in one reference, that's a novelty rejection.

A useful way to think about it: imagine an invention is A + B + C + D. If prior art shows A + B + C, it's probably novel. That fourth element is doing real work. Novelty, honestly, is not usually where applications fall apart.

So What's the Actual Problem?

Novelty is only the first requirement. An invention also has to be non-obvious, and that's a completely different question evaluated under a completely different standard. Most researchers, when they first hear this, assume those two things are basically the same. They're not. And conflating them is where a lot of strong science fails to become protected intellectual property.

The Harder Question: Is the Result Non-Obvious?

Why Scientific Logic Can Work Against Patent Law

This is the part that surprises university researchers most, because it runs directly counter to how scientists are trained to think and write.

Consider how a grant proposal works. It lays out the background: this study showed X, that study showed Y, and the logical next step is Z. It's a clear progression. It's persuasive. It's designed to make the reviewer think: of course this should be funded, it's the obvious next thing to try.

In patent law, that same paragraph is a roadmap to rejection. If an application reads like a grant proposal, building block by building block toward an inevitable conclusion, the scientist has essentially argued that a person skilled in the field would have gotten there anyway. That's the definition of obvious. And obvious inventions don't get patents.

The standard the United States Patent and Trademark Office applies is called the "person of ordinary skill in the art," someone with the same training, familiarity with the literature, and baseline competence as the inventor. The question is whether that person would have found it obvious to combine the prior art and arrive at the same result. Not whether someone actually did. Not whether it was easy. Whether it was predictable.

The Data Researchers Are Undervaluing

The most useful thing a researcher can bring to a non-obviousness argument is a result the field didn't see coming. If the prior art says combining two elements gives a +10 result on whatever metric is being measured, and the actual result is +20, that gap is significant. The literature didn't predict it. A person of ordinary skill wouldn't have expected it. That's not just a strong scientific finding; it's evidence of an inventive step.

When we sit down with researchers to evaluate an invention, we're looking for exactly this. Not the results that confirm the hypothesis, but the ones that surprised even the researcher. Scientists tend to treat those as secondary, interesting maybe, worth a footnote, something to explore in the next paper. In a patent application, they're often the most important data in the file.

What This Means for How Researchers Document Their Work

Failures Are Part of the Argument

One of the first questions we ask in an invention intake meeting: what didn't work? Not as small talk, as strategy.

The history of failed attempts, dead ends, and prior art that pointed in the wrong direction is some of the most useful material in a non-obviousness argument. If the existing literature actively taught away from the researcher's approach, if someone published that combining two components would be inoperable or that the chemistry wouldn't allow it, and the researcher found a way anyway, that context helps explain why the result wasn't obvious. It tells the story of why no one had gotten there before.

Researchers keeping a lab notebook should think of it as documentation for two audiences: the principal investigator and the patent attorney.

Scientific Writing vs. Patent Writing

In a manuscript, leading the reader step by step toward a conclusion is the goal. It should feel inevitable. That's the whole point.

In a patent application, that same instinct leads to rejection. The science still needs to be there, enough to show the invention works and that someone could reproduce it, but the application can't construct the kind of logical progression that suggests any trained researcher in the field would have arrived at the same place. It's a fine tightrope to walk, and one that shifts with every application we help bring forward.

It's also part of why strategic patent drafting works best when scientists are in the room from the start, not brought in to translate after the legal framework is already set. At a firm where 92% of attorneys and patent agents hold PhDs, that collaboration happens by default. It makes a real difference in how an application holds up through prosecution.
 

Questions Researchers Ask Us Before They File

These come up in almost every conversation we have with university inventors. For researchers at the stage of wondering whether to move forward, these answers matter.

Can publishing a paper before filing hurt patent chances?

Yes, and this is one of the most consequential mistakes a researcher can make.

In the U.S., there's a one-year grace period: once an invention is publicly disclosed, there are 12 months to file before that disclosure counts as prior art against the application. A conference presentation, a preprint, a published paper, each one starts a clock. Miss the window, and the researcher's own work can be used to reject the application.

Outside the U.S., the situation is more unforgiving. Most countries, including those in Europe, have no meaningful grace period. Any public disclosure before the filing date can eliminate international options entirely. If protecting an invention globally is part of the IP strategy, the sequence is non-negotiable: file first, then publish.

Public disclosure is also broader than most researchers realize. It's not just journal articles. Conference presentations, poster sessions, publicly available abstracts, thesis defenses, and even some informal talks in non-confidential settings can qualify. When in doubt, assume it counts.

When should a researcher reach out, and how early is too early?

As soon as a client believes they have something, put a flag in the ground. Before any public disclosure. Before the conference abstract is due. Before the paper goes out for review.

Filing a provisional application at that point gives the client a priority date, a timestamp that establishes when the invention existed. It doesn't need to be perfect. It doesn't lock into final claims. What it does is buy 12 months to keep developing the work, gather more data, and prepare a complete nonprovisional application, all while the filing date is already protected.

The instinct to wait until the science is more complete is understandable. But in patent law, earlier is almost always better. A patentability assessment early in the process helps clients understand what they have and identify the data that would most strengthen the application before committing to a full filing.

Where We've Landed

Neither of us expected to spend this much time thinking about what "obvious" means. But the further we get into patent prosecution, the clearer it becomes that the science and the legal strategy aren't separate tracks. They're the same conversation, and how a researcher handles the early stages shapes everything downstream.

Three things we'd leave any client with: novelty is the starting point, not the finish line. Non-obviousness is where the real argument happens, and unexpected results, the ones that might have been buried in a footnote, are often the strongest asset in the application. And file before publishing, every time, without exception.

If you have a discovery worth evaluating, reach out to the team at PPG. We'll ask the questions your lab notebook hasn't answered yet.